However, in general, CD14+HLA-DRlow/− MDSCs appear to disturb systemic immunity during CLL disease progression, predominantly by inhibiting the CD4+ T-cell response. The gene discussed is CD4; the disease is B-cell chronic lymphocytic leukemia.